CD19-directed chimeric antigen receptor-modified T (CAR-T) cells exhibit powerful capability to eliminate leukemia cells and showed a high CR rate and curable effect in patients with relapsed ALL [1, 2]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.